This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Winter is coming: managing COPD exacerbations in the current environment

Winter is coming: managing COPD exacerbations in the current environment

Dr Emmet O’Brien, Consultant Respiratory Physician Beaumont Hospital, Dublin

Webinar | 23rd September | 01:00 PM GMT

PM-IE-CPU-WCNT-200007

Register now

Winter is coming: managing COPD exacerbations in the current environment

Winter is coming: managing COPD exacerbations in the current environment

Dr Emmet O’Brien, Consultant Respiratory Physician Beaumont Hospital, Dublin

Webinar | 23rd September | 01:00 PM GMT

PM-IE-CPU-WCNT-200007

Register now

Upcoming Events and News

GSK upcoming events and latest news for Healthcare Professionals.

Access free resources

Order resources to support your patients including, samples, demo devices, leaflets plus more.

See what's available

Educational webinars

Join your peers and healthcare experts at live webinars run by GSK.

Webinars on demand

Catch up on Asthma & COPD video webinars anytime from the comfort of your own office.

Upcoming Events and News

GSK upcoming events and latest news for Healthcare Professionals.

What's coming up?

Access free resources

Order resources to support your patients including, samples, demo devices, leaflets plus more.

See what's available

Educational webinars

Join your peers and healthcare experts at live webinars run by GSK.

What's coming up?

Webinars on demand

Catch up on Asthma & COPD video webinars anytime from the comfort of your own office.

Explore more

Respiratory Products

Relvar Ellipta

25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1

Trelegy▼ Ellipta

Discover more about the only once daily COPD single inhaler triple therapy available in Ireland.

Anoro▼ Ellipta

Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class.

Respiratory Products

Relvar Ellipta

25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1

Trelegy▼ Ellipta

Discover more about the only once daily COPD single inhaler triple therapy available in Ireland.

Anoro▼ Ellipta

Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class. 2

More Information

Dovato (dolutegravir and lamivudine)

An innovative treatment for your patients living with HIV-1. Dovato is a complete two-drug regimen, offering convenient dosing, available in a once daily pill.

Learn more

Prescribing information

Explore Bexsero - Meningococcal Group B Vaccine

Bexsero is indicated for the active immunisation of individuals from 2 months of age and older against invasive meningococcal disease(IMD) caused by Neisseria meningitidis group B.

Learn more

Prescribing information

Using dual therapy or triple therapy for your patients?

The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI). 2

Explore the IMPACT data

Prescribing information

Stay Informed

Sign up to receive email alerts from GSK including important supply updates, new product information and events we are running.

Register Now

Abbreviations

FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References:

  1. Woodcock A et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel-group, randomised controlled trial. Lancet 2017;290:22247-2255.
  2. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.